Clinical Study Of Ulinastatin Combined With Ambroxol For The Treatment Of Acute Exacerbation Of Chronic Obstructive Pulmonary Disease With Type Ⅱ Respiratory Failure

Objectives To explore the therapeutic efficacy of ulinastain combined with Ambroxol for the treatment of acute exacerbation of chronic obstructive pulmonary disease with typeⅡrespiratory failure.Methods A total of 60 patients with AECOPD were divided into four groups A,B,C and D,with 15 patients in each group.The therapeutic schedule were as follows:Patients in group A received only routine treatment;Patients in group B were treated with conventional therapy+ambroxol;Patients in group C received conventional therapy+ulinastatin;Patients in group D received conventional treatment+ulinastatin combined with ambroxol.The general information of each patient was recorded before ICU treatment（including age,gender,course of disease,heart rate,blood sugar,hypertension,etc.）.White blood cells in the blood and inflammatory factor（CRP and PCT）content,blood gas analysis results and the APACHEⅡscores were recorded before and after seven days’ ICU treatment,respectively.We also analyzed the patient’s intubation rate and the duration of ICU treatment.Results 1 Through the analysis of WBC,CRP and PCT of AECOPD patients after seven days’ ICU treatment,we found that the content of WBC,CRP and PCT of patients in group D decreased significantly,compared with those of patients in group A,B and C,the differences were statistically significant,P<0.05.2 By the analysis of arterial blood gas analysis of AECOPD patients after seven days’ ICU treatment,we found that PCO₂ of patients in group D decreased significantly and PO2 increased significantly,compared with those of patients in group A,B and C,the differences were statistically significant,P<0.05.3 By the analysis of intubation rate and the duration of ICU treatment of AECOPD patients,we found that there was no significant difference in intubation rate of patients in group D,compared with those of patients in group A,B and C,P>0.05;however,the duration of ICU treatment of patients in group D decreased significantly,the differences were statistically significant,P<0.05.Conclusions 1 In contrast to the single application of ustradin or ambroxol and conventional treatment,the application of ustodine combined with ambroxol could significantly relieve the inflammatory response of AECOPD patients with typeⅡrespiratory failure.2 With the single application of ulinastatin or ammonia and conventional treatment,the application of ulinastatin combined ammonia could more effectively improve lung function for patients with AECOPD combination of typeⅡrespiratory failure,reduce CO2 retention and correct hypoxia state.3 The combined application of ulinastatin combined with ambroxol could not reduce the intubation rate of AECOPD patients with typeⅡrespiratory failure,but it could significantly reduce the duration of ICU treatment and reduce hospitalization costs.